Related Experiment Video
Updated: Feb 12, 2026

Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell MSC Spheroids Primed in 3-D Cultures Under Xeno-free Conditions
Published on: March 18, 2017
Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance
Jonathan Edward Millar1, Viktor von Bahr1,2, Maximillian V Malfertheiner1,3
1Critical Care Research Group, University of Queensland, Brisbane, Queensland, Australia.
Abstract:
Mesenchymal stem cells (MSCs) have attracted attention as a potential therapy for Acute Respiratory Distress Syndrome (ARDS). At the same time, the use of extracorporeal membrane oxygenation (ECMO) has increased among patients with severe ARDS. To date, early clinical trials of MSCs in ARDS have excluded patients supported by ECMO. Here we provide evidence from an ex-vivo model of ECMO to suggest that the intravascular administration of MSCs during ECMO may adversely impact the function of a membrane oxygenator. The addition of clinical grade MSCs resulted in a reduction of flow through the circuit in comparison to controls (0.6 ±0.35 L min-1vs 4.12 ± 0.03 L min-1, at 240 minutes) and an increase in the transoygenator pressure gradient (101±9 mmHg vs 21±4 mmHg, at 240 minutes). Subsequent immunohistochemistry analysis demonstrated quantities of MSCs highly adherent to membrane oxygenator fibres. This study highlights the potential harm associated with MSC therapy during ECMO and suggests further areas of research required to advance the translation of cell therapy in this population.
Insights
Mesenchymal stem cells (MSCs) administered during extracorporeal membrane oxygenation (ECMO) may impair oxygenator function. This study shows MSCs reduce flow and increase pressure in ECMO circuits, highlighting potential risks for severe Acute Respiratory Distress Syndrome (ARDS) patients.
Area of Science:
- Regenerative Medicine
- Critical Care Medicine
- Biomedical Engineering
Background:
- Mesenchymal stem cells (MSCs) show promise for treating Acute Respiratory Distress Syndrome (ARDS).
- Extracorporeal membrane oxygenation (ECMO) is increasingly used for severe ARDS.
- Current MSC trials exclude patients on ECMO.
Purpose of the Study:
- To investigate the impact of intravascular Mesenchymal stem cell (MSC) administration on membrane oxygenator function during extracorporeal membrane oxygenation (ECMO).
- To assess potential adverse effects of combining MSC therapy with ECMO support in a simulated setting.
Main Methods:
- An ex-vivo model simulating ECMO circuits was utilized.
- Clinical grade MSCs were added to the ECMO circuit, and their effect on flow and pressure was measured.
- Immunohistochemistry was performed to analyze MSC adhesion to the oxygenator fibers.
Main Results:
- Addition of MSCs significantly reduced circuit flow (0.6 ±0.35 L/min vs 4.12 ± 0.03 L/min at 240 min).
- MSCs caused a marked increase in the trans-oxygenator pressure gradient (101±9 mmHg vs 21±4 mmHg at 240 min).
- Immunohistochemistry confirmed extensive MSC adherence to membrane oxygenator fibers.
Conclusions:
- Intravascular administration of MSCs during ECMO may adversely affect membrane oxygenator function.
- Potential risks include reduced circuit flow and increased pressure, necessitating further research.
- This finding is critical for advancing cell therapy translation in ECMO-supported ARDS patients.
More Related Videos
Related Concept Videos
Mesenchymal Stem Cells
Magnetic Declination
Adult Stem Cells
Conservation of Declining Populations
Embryonic Stem Cells
Induced Pluripotent Stem Cells

